Chatbot coaches cancer survivors on genetic testing
NCT ID NCT06184867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatbot made genetic testing easier to understand and use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: User/Usability Testing 1. Age 18 or older 2. Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer 3. Speak/read and understand English 4. Capable of providing informed consent 5. Have Internet access (via smartphone, tablet, or computer) Randomized Feasibility Trial 1. Age 18 or older 2. Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer 3. Meet National Comprehensive Cancer Network (NCCN) criteria for germline GT 4. Speak/read and understand English 5. Capable of providing informed consent 6. Have Internet access (via smartphone, tablet or computer) Exclusion Criteria: Participants will be 18 years of age or older because germline genetic testing is generally not recommended in children when the test results would not impact clinical management. Participants from the user and usability testing phases are not eligible for the feasibility trial. Feasibility trial participants cannot have previously undergone germline GT for hereditary cancer risk.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Radioactive missile aims at prostate cancer that spread
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?